Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-kappa B Signaling Pathway

doi:10.3389/fphar.2020.610772

	Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-kappa B Signaling Pathway
	Du, Yarong 2,3,4; Jia, Cong 4; Liu, Yan 4; Li, Yehua 4; Wang, Jufang 1,2,3; Sun, Kun 4
刊名	FRONTIERS IN PHARMACOLOGY
	2021-01-25
卷号	11 页码:12
关键词	isorhamnetin IL-13 NF-kB radiosensitivity radiotherapy
ISSN号	1663-9812
DOI	10.3389/fphar.2020.610772
通讯作者	Sun, Kun(kunsun@nwnu.edu.cn)
英文摘要	Isorhamnetin (ISO), a naturally occurring plant flavonoid, is widely used as a phytomedicine. The major treatment modality for non-small-cell lung carcinoma (NSCLC) is radiotherapy. However, radiotherapy can induce radioresistance in cancer cells, thereby resulting in a poor response rate. Our results demonstrated that pretreatment with ISO induced radiosensitizing effect in A549 cells using colony formation, micronucleus, and gamma H2AX foci assays. In addition, ISO pretreatment significantly enhanced the radiation-induced incidence of apoptosis, the collapse of mitochondrial membrane potential, and the expressions of proteins associated with cellular apoptosis and suppressed the upregulation of NF-kappa Bp65 induced by irradiation in A549 cells. Interestingly, the expression of interleukin-13 (IL-13), an anti-inflammatory cytokine, was positively correlated with the ISO-mediated radiosensitization of A549 cells. The knockdown of IL-13 expression by RNA interference decreased the IL-13 level and thus reduced ISO-mediated radiosensitivity in cells. We also found that the IR-induced NF-kappa B signaling activation was inhibited by ISO pretreatment, and it was abrogated in IL-13 silenced cells. We speculated that ISO may confer radiosensitivity on A549 cells via increasing the expression of IL-13 and inhibiting the activation of NF-kappa B. To our knowledge, this is the first report demonstrating the effects of ISO treatment on the responsiveness of lung cancer cells to irradiation through IL-13 and the NF-kappa B signaling pathway. In summary, ISO is a naturally occurring radiosensitizer with a potential application in adjuvant radiotherapy.
资助项目	National Natural Science Foundation of China[11705248] ; National Natural Science Foundation of China[31660060] ; Science and Technology Research Project of Gansu Province[145RTSA012] ; Science and Technology Research Project of Gansu Province[17JR5RA307]
WOS研究方向	Pharmacology & Pharmacy
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000615810800001
资助机构	National Natural Science Foundation of China ; Science and Technology Research Project of Gansu Province
内容类型	期刊论文
源URL	[http://119.78.100.186/handle/113462/138035]
专题	中国科学院近代物理研究所
通讯作者	Sun, Kun
作者单位	1.Univ Chinese Acad Sci, Sch Nucl Sci & Technol, Beijing, Peoples R China 2.Chinese Acad Sci, Inst Modern Phys, CAS Key Lab Heavy Ion Radiat Biol & Med, Lanzhou, Peoples R China 3.Chinese Acad Sci, Inst Modern Phys, Key Lab Space Radiobiol Gansu Prov, Lanzhou, Peoples R China 4.Northwest Normal Univ, Coll Life Sci, Lanzhou, Peoples R China
推荐引用方式 GB/T 7714	Du, Yarong,Jia, Cong,Liu, Yan,et al. Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-kappa B Signaling Pathway[J]. FRONTIERS IN PHARMACOLOGY,2021,11:12.
APA	Du, Yarong,Jia, Cong,Liu, Yan,Li, Yehua,Wang, Jufang,&Sun, Kun.(2021).Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-kappa B Signaling Pathway.FRONTIERS IN PHARMACOLOGY,11,12.
MLA	Du, Yarong,et al."Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-kappa B Signaling Pathway".FRONTIERS IN PHARMACOLOGY 11(2021):12.